Erratum to: Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study

Non-invasive Auricular Vagus Nerve Stimulation as a Potential Treatment for Covid19-Originated Acute Respiratory Distress Syndrome

“…aVNS resulted in an increase of the middle cerebral and supratrochlear artery blood flow velocity in human subjects (Széles and Litscher, 2004 ) and a decrease of the velocity of the carotid-femoral flow (Hackl et al, 2017 ). aVNS diminishes systolic blood pressure in subjects with coronary artery diseases as well as in subjects with dysfunctions of glucose metabolism (Zamotrinsky et al, 2001 ; Huang et al, 2014 ; Stavrakis et al, 2015 ) it suppresses atrial fibrillation in patients with paroxysmal atrial fibrillation (Afanasiev et al, 2016 ) and reliefs anginal symptoms in coronary artery disease patients (Zamotrinsky et al, 1997 ). aVNS improves cardiac baroreflex sensitivity (Antonino et al, 2017 ), increases capillary-venous oxygenation in deep tissues in diabetic patients (Kaniusas et al, 2015 ), increases skin temperature in human subjects with disfunctions of the peripheral arteries and chronic diabetic wounds (Szeles et al, 2013 ) and improves symptoms in peripheral arterial occlusive diseases (Payrits et al, 2011 ).…”

“…Systemic effects of aVNS are additionally supported by improvement of metabolic processes (Richards and Marley, 1998 ; Cabýoglu et al, 2006 ; Huang et al, 2014 ; Ju et al, 2014 ; Schukro et al, 2014 ), attenuation of neurological disorders (Kraus et al, 2007 ; Hein et al, 2013 ; Lehtimäki et al, 2013 ; Kampusch et al, 2015 ; Bauer et al, 2016 ; Fang et al, 2016 ; Rong et al, 2016 ; Capone et al, 2017 ; Ylikoski et al, 2017 ) and enhancement of cognitive performances (Rong et al, 2012 ; Jacobs et al, 2015 ) as well as by pain relief effects (Sator-Katzenschlager et al, 2003 , 2004 ; Napadow et al, 2012 ; Chakravarthy et al, 2015 ; Kox et al, 2015 ; Kwan et al, 2016 ; French et al, 2017 ; Hoover, 2017 ; Kovacic et al, 2017 ; Kaniusas et al, 2019a , b ).…”

Prescription Factors Associated with Medication Non-adherence in Japan Assessed from Leftover Drugs in the SETSUYAKU-BAG Campaign: Focus on Oral Antidiabetic Drugs

“…Preprandial administration was associated with lower medication adherence compared to postprandial administration. Masuda et al mentioned that one reason for non-adherence to αGI therapy is the need to take these drugs before meals (Masuda et al, 2011 ). While little has been reported about the influence of preprandial dosing on medication adherence, αGI are frequently prescribed in Japan and we found that αGI accounted for 14% of all the OAD formulations.…”

International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020)

“…A pilot study of tVNS in schizophrenia found no effect on symptom severity (Hasan et al, 2015 ). Moreover, many potential targets for treatment via tVNS have been suggested, including attention deficit hyperactivity disorder (ADHD) (Beste et al, 2016 ), autism spectrum disorders (Jin and Kong, 2016 ), Alzheimer's dementia (Jacobs et al, 2015 ), post-operative cognitive dysfunction (Xiong et al, 2009 ), increased risk of type II diabetes (Huang et al, 2014 ), preterm infants with oromotor dysfunction (Badran et al, 2020 ), chronic stroke patients (Capone et al, 2017 ), coronary insufficiency (Afanasiev et al, 2016 ) and chronic migraine (Straube et al, 2015 ). The idea that tVNS might be a promising treatment in Alzheimer's dementia has received support through recent evidence that tVNS can recover impaired microglia function in a mouse model of Alzheimer's dementia (Kaczmarczyk et al, 2017 ; Huffman et al, 2019 ), and there is an ongoing clinical trial of tVNS as a treatment for mild cognitive impairment (NCT03359902).…”